Physician profile
Robert D Runk
NPI 1093791584
$1,156.40
in general payments reported to CMS, 2019-2025
12 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.01 · 2022: $123 · 2023: $490 · 2024: $13.73 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $329.28 | 2021-2025 | Breztri, Airsupra |
| Abbvie INC. | $222.44 | 2022-2023 | |
| Silk Road Medical, INC. | $146.05 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $112.70 | 2023 | Quviviq |
| Intuitive Surgical, INC. | $96.58 | 2023 | Da Vinci Surgical System |
| Inogen, INC. | $29.26 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.44 | 2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.46 | 2025 | Caplyta |
| Lilly USA, LLC | $18.91 | 2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $16.53 | 2025 | Gattex |
| Glaxosmithkline, LLC. | $15.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Runk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.